Faculty of Health, Department of Nutrition and Dietetics, University of Canberra, Australia.
University of Canberra, Canberra, Australia.
Nutr Metab Cardiovasc Dis. 2021 Nov 29;31(12):3282-3304. doi: 10.1016/j.numecd.2021.09.003. Epub 2021 Sep 21.
Circulating vitamin D is linked with the risk of cardiovascular disease (CVD). A meta-analysis has yet to explicitly explore correlation between vitamin D and the risk of CVD incidence and recurrent CVD. This meta-analysis examines the association between 25-hydroxy-vitamin D (25(OH)D) and the risk of CVD incidence (fatal, non-fatal, fatal and non-fatal combined events) and the risk of recurrent CVD (fatal, recurrent, and fatal and recurrent combined events). PROSPERO registration-CRD42021251483.
A total of 79 studies (46 713 CVD cases in 1 397 831 participants) were included in the meta-analysis, of which 61 studies examined the risk of CVD incidence events, and 18 studies examined risk of recurrent CVD events. The risk of CVD incidence events (RR = 1.34, 95% CI: 1.26-1.43, p < 0.001) and recurrent CVD events (RR = 1.86, 95% CI: 1.46-2.36, p < 0.001) was higher in the lowest than the highest category of circulating 25(OH)D. Dose-response analysis reported a linear association for every 10 ng/ml increment of 25(OH)D and non-fatal CVD incidence events (RR = 0.94; 95% CI = 0.89-0.98, p = 0.005), lower fatal recurrent CVD events (RR = 0.45; 95% CI = 0.32-0.62, p < 0.001) and lower combined recurrent CVD events (RR = 0.80; 95% CI = 0.65-0.97, p = 0.023). A non-linear association was observed between higher 25(OH)D and lower fatal CVD incidence events (P-nonlinear<0.001), lower combined CVD incidence events (P-nonlinear = 0.001), and lower non-fatal recurrent CVD events (P-nonlinear = 0.044).
The lowest category of circulating 25(OH)D was associated with a higher risk of CVD incidence events and recurrent CVD events.
循环维生素 D 与心血管疾病(CVD)风险相关。荟萃分析尚未明确探讨维生素 D 与 CVD 发病风险和复发性 CVD 之间的相关性。本荟萃分析研究了 25-羟维生素 D(25(OH)D)与 CVD 发病风险(致命、非致命、致命和非致命综合事件)和复发性 CVD 风险(致命、复发和致命和复发综合事件)之间的关联。PROSPERO 注册-CRD42021251483。
共有 79 项研究(1397831 名参与者中 46713 例 CVD 病例)纳入荟萃分析,其中 61 项研究检测了 CVD 发病事件的风险,18 项研究检测了复发性 CVD 事件的风险。最低与最高循环 25(OH)D 类别相比,CVD 发病事件(RR=1.34,95%CI:1.26-1.43,p<0.001)和复发性 CVD 事件(RR=1.86,95%CI:1.46-2.36,p<0.001)的风险更高。剂量反应分析报告了每增加 10ng/ml 25(OH)D 与非致命性 CVD 发病事件(RR=0.94;95%CI=0.89-0.98,p=0.005)的线性关联,致命性复发性 CVD 事件(RR=0.45;95%CI=0.32-0.62,p<0.001)和复发性 CVD 综合事件(RR=0.80;95%CI=0.65-0.97,p=0.023)的风险降低。在较高的 25(OH)D 与较低的致命性 CVD 发病事件(P非线性<0.001)、较低的综合 CVD 发病事件(P非线性=0.001)和较低的非致命性复发性 CVD 事件(P非线性=0.044)之间观察到非线性关联。
最低循环 25(OH)D 类别与 CVD 发病事件和复发性 CVD 事件的风险增加相关。